发明申请
US20150202294A1 USE OF PSORALEN DERIVATIVES AND COMBINATION THERAPY FOR TREATMENT OF CELL PROLIFERATION DISORDERS
有权
PSORALEN衍生物的使用和用于治疗细胞增殖障碍的组合治疗
- 专利标题： USE OF PSORALEN DERIVATIVES AND COMBINATION THERAPY FOR TREATMENT OF CELL PROLIFERATION DISORDERS
- 专利标题（中）： PSORALEN衍生物的使用和用于治疗细胞增殖障碍的组合治疗
-
申请号： US14603539申请日： 2015-01-23
-
公开(公告)号： US20150202294A1公开(公告)日： 2015-07-23
- 发明人: Wenle XIA , David GOODEN , Erik J. SODERBLOM , Eric J. TOONE , Neil L. SPECTOR , Wayne F. BEYER, JR. , Harold WALDER
- 申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
- 申请人地址： US MI Detroit US NC Durham
- 专利权人： IMMUNOLIGHT, LLC,DUKE UNIVERSITY
- 当前专利权人： IMMUNOLIGHT, LLC,DUKE UNIVERSITY
- 当前专利权人地址： US MI Detroit US NC Durham
- 主分类号： A61K41/00
- IPC分类号： A61K41/00 ; A61K51/12 ; A61K31/37 ; A61K31/4709 ; A61K31/436 ; A61K31/517
摘要：
Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
公开/授权文献
信息查询
